On June 12, RemeGen (09995.HK) rose 5.38% in regular trading, trading at HK$73.0/share, with turnover of HK$160 million. The stock continues its upward momentum following the landmark dual indication approval for its core product Telitacicept.

On June 8, China's NMPA approved Telitacicept for the treatment of Sjogren's syndrome and IgA nephropathy, bringing the drug's total approved indications to five. Telitacicept is the world's first BLyS/APRIL dual-target biologic approved for Sjogren's syndrome and the first domestic dual-target biologic for IgA nephropathy. The Sjogren's trial was the first globally to achieve strong positive Phase III results for a dual-target biologic in this disease area, while IgA nephropathy data were published in The New England Journal of Medicine.

Analysts project Telitacicept's China peak sales could reach RMB 14 billion with these expanded indications. The drug generated over RMB 1.3 billion in sales in 2025 across its prior three indications, representing 42.7% of company revenue. Additional indications including ocular myasthenia gravis and connective tissue disease-related interstitial lung disease remain in Phase III trials.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)